Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining Emerging Gene-editing Therapies for alpha-1 antitrypsin deficiency (AATD), including Beam Therapeutics' BEAM-302

Ticker(s): BEAM, TAK, GRFS, KMDA

Who's the expert?

Institution: Blessing Health System/ Hannibal Clinic

Pulmonologist at Blessing Heath Hannibal Clinic
Manages over 400 patients at an Alpha-1 certified center and research center
Primary research interest in AATD and developing therapies

Interview Goal

The goal of this call is to understand the current treatment landscape for alpha-1 antitrypsin deficiency (AATD), and evaluate how emerging gene-editing therapies like BEAM-302 may impact clinical outcomes, durability of response, and future standard of care

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.